Treatment of nephrogenic systemic fibrosis: limited options but hope for the future

Semin Dial. 2008 Mar-Apr;21(2):155-9. doi: 10.1111/j.1525-139X.2007.00407.x. Epub 2008 Jan 23.

Abstract

Nephrogenic systemic fibrosis has now been linked to gadolinium-based contrast exposure in those with compromised kidney function. When present, symptoms can be quite devastating for the patient including severe pain and immobility. Unfortunately there is a lack of a universally effective therapy at this time and the literature, reviewed in this article, is comprised of primarily case reports and small case series allowing few conclusions to be drawn. It is widely recognized that supportive management with physical therapy and aggressive pain management is essential. Resolution of renal function in acute kidney injury appears to attenuate disease in most cases and transplantation has been associated with variable success. Therapies with anecdotal benefit include extracorporeal photopheresis and intravenous sodium thiosulfate. Other interventions have shown limited success. As the mechanism becomes more readily understood, it is hoped that targeted therapy might prove more effective than currently available remedies. In all likelihood prevention will prove to be most effective in avoiding this devastating complication.

Publication types

  • Review

MeSH terms

  • Contrast Media / adverse effects*
  • Fibrosis / diagnosis
  • Fibrosis / etiology*
  • Fibrosis / therapy*
  • Gadolinium / adverse effects*
  • Humans
  • Immunotherapy
  • Kidney Failure, Chronic / complications*
  • Kidney Failure, Chronic / pathology
  • Kidney Failure, Chronic / therapy
  • Phototherapy
  • Renal Replacement Therapy

Substances

  • Contrast Media
  • Gadolinium